17 results
10-K
2021 FY
EX-10.13
CADL
Candel Therapeutics Inc
29 Mar 22
Annual report
8:46am
such inspection.
(e) Consultant will not use any confidential information or trade secrets of any third party in his engagement by Company in violation
S-1/A
EX-10.5.6
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
or trade secrets of any third party in his engagement by Company in violation of the terms of the agreements under which he had access to or knowledge
10-K
2021 FY
EX-10.12
CADL
Candel Therapeutics Inc
29 Mar 22
Annual report
8:46am
, other than confidentiality restrictions (if any), or the Executive’s engagement in any business of the Company’s. The Executive represents … ”) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company:
No inventions
S-1/A
EX-10.5.5
CADL
Candel Therapeutics Inc
16 Jul 21
IPO registration (amended)
6:07am
engagement in any business of the Company’s. The Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s
S-1/A
EX-10.5.4
grv62qk5pzksuouj
16 Jul 21
IPO registration (amended)
6:07am
8-K
EX-99.1
tfniugoj
6 Dec 22
Regulation FD Disclosure
8:01am
S-1/A
EX-10.6
vmf4xi7j39dg pzxnz
16 Jul 21
IPO registration (amended)
6:07am
S-1/A
EX-10.5.1
jlx2 zdm7ey0
16 Jul 21
IPO registration (amended)
6:07am
DEF 14A
b0bm9k
2 Sep 22
Definitive proxy
8:30am
10-K
l0fhgzy
29 Mar 22
Annual report
8:46am
- Prev
- 1
- Next